Pharmascience Inc v Teva Canada Innovation 2022 FCA 207 Monaghan JA: Gleason, Mactavish JJA
2,702,437 / 2,760,802 / glatiramer acetate / Copaxone / Glatect / NOC /
I don’t usually blog on procedural issues, but this decision on an appeal from a costs award affirms a simple point: “settlement proposals or offers that do not meet the conditions of Rule 420 may be considered under Rule 400 in making a costs award” [18].
No comments:
Post a Comment